Killing the hypnozoite - drug discovery approaches to prevent relapse in Plasmodium vivax

被引:77
作者
Campo, Brice [1 ]
Vandal, Omar [2 ]
Wesche, David L. [2 ,3 ]
Burrows, Jeremy N. [1 ]
机构
[1] Med Malaria Venture, Geneva, Switzerland
[2] Bill & Melinda Gates Fdn, Seattle, WA USA
[3] Great Lakes Drug Dev Certara, Princeton, NJ USA
关键词
Plasmodium vivax; Radical cure; Hypnozoite; Strategy; Drug discovery assays; IN-VITRO CULTURE; LIVER STAGE; MALARIA PARASITES; EXOERYTHROCYTIC PARASITES; ANTIMALARIAL ACTIVITY; FALCIPARUM-MALARIA; HUMAN HEPATOCYTES; RADICAL CURE; MOUSE MODELS; PRIMAQUINE;
D O I
10.1179/2047773215Y.0000000013
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The eradication of malaria will only be possible if effective, well-tolerated medicines kill hypnozoites in vivax and ovale malaria, and thus prevent relapses in patients. Despite progress in the 8-aminoquinoline series, with tafenoquine in Phase III showing clear benefits over primaquine, the drug discovery challenge to identify hypnozoiticidal or hypnozoite-activating compounds has been hampered by the dearth of biological tools and assays, which in turn has been limited by the immense scientific and logistical challenges associated with accessing relevant human tissue and sporozoites. This review summarises the existing drug discovery series and approaches concerning the goal to block relapse.
引用
收藏
页码:107 / 122
页数:16
相关论文
共 115 条
  • [81] Price R N., 2014, The Lancet Infectious Diseases, V3099, P1
  • [82] Vivax malaria: Neglected and not benign
    Price, Ric N.
    Tjitra, Emiliana
    Guerra, Carlos A.
    Yeung, Shunmay
    White, Nicholas J.
    Anstey, Nicholas M.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 77 (06) : 79 - 87
  • [83] QUINOLINE ESTERS AS POTENTIAL ANTIMALARIAL-DRUGS - EFFECT ON RELAPSES OF PLASMODIUM-CYNOMOLGI INFECTIONS IN MONKEYS
    PURI, SK
    DUTTA, GP
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1990, 84 (06) : 759 - 760
  • [84] Plasmodium cynomolgi:: Gametocytocidal activity of the anti-malarial compound CDRI 80/53 (elubaquine) in rhesus monkeys
    Puri, SK
    Dutta, GP
    [J]. EXPERIMENTAL PARASITOLOGY, 2005, 111 (01) : 8 - 13
  • [85] The metabolism of primaquine to its active metabolite is dependent on CYP 2D6
    Pybus, Brandon S.
    Marcsisin, Sean R.
    Jin, Xiannu
    Deye, Gregory
    Sousa, Jason C.
    Li, Qigui
    Caridha, Diana
    Zeng, Qiang
    Reichard, Gregory A.
    Ockenhouse, Christian
    Bennett, Jason
    Walker, Larry A.
    Ohrt, Colin
    Melendez, Victor
    [J]. MALARIA JOURNAL, 2013, 12
  • [86] Recht J., 2014, SAFETY 8 AMINOQUINOL
  • [87] Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity
    Rochford, Rosemary
    Ohrt, Colin
    Baresel, Paul C.
    Campo, Brice
    Sampath, Aruna
    Magill, Alan J.
    Tekwani, Babu L.
    Walker, Larry A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (43) : 17486 - 17491
  • [88] Targeting the Liver Stage of Malaria Parasites: A Yet Unmet Goal
    Rodrigues, Tiago
    Prudencio, Miguel
    Moreira, Rui
    Mota, Maria M.
    Lopes, Francisca
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 995 - 1012
  • [89] Development and function of human innate immune cells in a humanized mouse model
    Rongvaux, Anthony
    Willinger, Tim
    Martinek, Jan
    Strowig, Till
    Gearty, Sofia V.
    Teichmann, Lino L.
    Saito, Yasuyuki
    Marches, Florentina
    Halene, Stephanie
    Palucka, A. Karolina
    Manz, Markus G.
    Flavell, Richard A.
    [J]. NATURE BIOTECHNOLOGY, 2014, 32 (04) : 364 - U230
  • [90] Human Hemato-Lymphoid System Mice: Current Use and Future Potential for Medicine
    Rongvaux, Anthony
    Takizawa, Hitoshi
    Strowig, Till
    Willinger, Tim
    Eynon, Elizabeth E.
    Flavell, Richard A.
    Manz, Markus G.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 31, 2013, 31 : 635 - 674